Dr. Gomella on AUA's New Prostate Cancer Guidelines

Leonard G. Gomella, MD
Published: Wednesday, May 08, 2013

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the clinical guidelines released by the American Urological Association (AUA) at its 2013 Annual Meeting.

The new guidelines for patients with castration-resistant prostate cancer (CRPC) are an important highlight from the AUA meeting, Gomella states. These guidelines include recommendations on PSA screening and the use of radiation therapy following radical prostatectomy. The guidelines on PSA screening will likely continue to fuel controversy on this topic, Gomella expects.

Overall, Gomella feels, the topics included in these guidelines will attract a great deal of national attention, since they address many of the challenges that physicians are currently facing in the treatment of men with prostate cancer.

<<< View more from the 2013 AUA Annual Meeting

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the clinical guidelines released by the American Urological Association (AUA) at its 2013 Annual Meeting.

The new guidelines for patients with castration-resistant prostate cancer (CRPC) are an important highlight from the AUA meeting, Gomella states. These guidelines include recommendations on PSA screening and the use of radiation therapy following radical prostatectomy. The guidelines on PSA screening will likely continue to fuel controversy on this topic, Gomella expects.

Overall, Gomella feels, the topics included in these guidelines will attract a great deal of national attention, since they address many of the challenges that physicians are currently facing in the treatment of men with prostate cancer.

<<< View more from the 2013 AUA Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x